All right, Democrats are calling for major changes within their party. And this week in New York, voters sent a clear message. Zohan Mandani, the 33-year-old self-described Democratic socialist, pulled off a huge upset against Andrew Cuomo and his million-dollar backings in the New York City mayoral primary election.Mani won 43% 43.5% to be exact of first place votes to Cuomo's 36.3%. And in his speech, he made clear that his run is not just about New York City. I will be your Democratic nominee for the may ...

Tonight we made history. [Applause] In the words of Nelson Mandela, "It always seems impossible until it is done." [Applause] Shock waves are still reverberating this week after 33-year-old Democratic socialist Zoran Mandani pulled off a major upset, defeating former Governor Andrew Cuomo in the Democratic primary for New York City mayor. Mdani's supporters say he represents just what the party needs.But some members of the Democratic establishment are reportedly melting down over his victory. And Republica ...

The party of Sheikh Hasina, the autocratic leader who was overthrown last year, has a dire record. But voters should have a free choice. We argue that Bangladesh should let the Awami League contest the next election https://t.co/BKO1sD7t97 ...

CNBC. com plus now. >> Zoran Mamdani's primary victory in New York City's mayoral race has sparked debate about the future of the Democratic Party across the country.Joining us right now is Bradley Tusk. He's the founder and CEO of Tusk Ventures, who also served as campaign manager for Mayor Bloomberg's successful 2009 bid. Bradley, welcome.Thanks for being here. Thanks for having me. Let's talk very quickly about what this means for New York.But I want to quickly get to the broader implications for the Dem ...

as a CEO who obviously has a workforce based in New York. Uh I you know what what will be your reaction. Will you change any of your strategic plans in terms of investing and or how you view your workforce if mom Donnie becomes the mayor.There are a lot of hypotheticals uh built into that question. First let's see what happens in the general election here in New York. Uh and then we have to see what policy changes uh happen.I would say that we are very committed to New York. the bar would be high for us to ...

Peter Orszag, Lazard CEO, joins 'Money Movers' to discuss the movement in the IPO market, M&A environment and the geopolitical climate and democratic party. ...

Tonight we made history. In the words of Nelson Mandela, it always seems impossible until it is done. My friends, we have done it.I will be your Democratic nominee for the mayor of New York City. [Applause] [Music] An hour ago, I spoke with Andrew Cuomo about the need to bring this city about the need to bring this city together. We have won because New Yorkers have stood up for a city they can afford. ...

Zohran Mamdani is poised to become the Democratic nominee for mayor of New York City after the 33-year-old democratic socialist forced his opponent Andrew Cuomo, the former governor of the state, to concede within hours after polls closed. Mamdani, who just months ago was an unfamiliar name to most New Yorkers, racked up commanding leads across Brooklyn, Queens and Manhattan, even pushing Cuomo close in what was meant to be his stronghold of the Bronx. “Eight months after launching this campaign with the vi ...

What you get from Zoran Mamdani is a guy who is really sort of committed himself to progressive issues, right. He says he's going to take buses and make them free. He says he's going to do city funded grocery stores.These are all big left proposals. Right. Very, very big liberal proposals that will have to be moderated at a certain point.And so that is what they're getting with him. They're getting a person who says that he's going to do these progressive policies. But what you really know is that with anyb ...

Core Insights - Rhythm Pharmaceuticals, Inc. announced the acceptance of three late-breaking abstracts for presentation at The Endocrine Society's Annual Meeting (ENDO 2025) scheduled for July 12-15 in San Francisco, CA [1] Group 1: Clinical Trials and Presentations - Dr. Susan Phillips will present data from the pivotal Phase 3 TRANSCEND trial evaluating setmelanotide for acquired hypothalamic obesity, marking it as the largest randomized, placebo-controlled trial in this area to date [2] - A poster presentation will be given by Dr. Christian Roth detailing exit interviews from 30 patients or caregivers in the US who participated in the Phase 3 TRANSCEND trial [2] - Dr. Vidhu Thaker will present results from a 14-week Phase 2 trial of bivamelagon, an oral MC4R agonist, in participants with acquired hypothalamic obesity [2] Group 2: Company Overview - Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company focused on rare neuroendocrine diseases, with its lead asset, IMCIVREE® (setmelanotide), approved by the FDA for treating obesity related to specific genetic conditions [3][4] - Setmelanotide is indicated for reducing excess body weight and maintaining weight reduction in patients aged 2 years and older with syndromic or monogenic obesity due to Bardet-Biedl syndrome or POMC, PCSK1, or LEPR deficiencies [4][5][6] - The company is advancing a broad clinical development program for setmelanotide and other investigational MC4R agonists, including bivamelagon and RM-718, as well as a preclinical suite for congenital hyperinsulinism [3]